EAACI Guidelines on the Management of IgE-mediated Food Allergy

Alexandra F Santos; Carmen Riggioni; Ioana Agache; Cezmi A Akdis; Mubeccel Akdis; Alberto Alvarez-Perea; Monsterrat Alvaro-Perea; Barbara Ballmer-Weber; Simona Barni; Kirsten Beyer; Carsten Bindslev-Jensen; Helen A. Brough; Betul Buyuktiryaki; Derek  Chu; Stefano Del Giacco; Audrey Dunn Galvin; Bernadette Eberlein; Motohiro Ebisawa; Philippe Eigenmann; Thomas Eiwegger; Mary Feeney; Monsterrat Fernandez-Rivas; Alessandro Fiocchi; Helen R. Fisher; David M. Fleischer; Mattia Giovannini; Claudia Gray; Karin Hoffmann-sommergruber; Susanne Halken; Jonathan O'B Hourihane; Christina J. Jones; Marek Jutel; Edward F Knol; George N. Konstantinou; Gideon Lack; Susanne Lau; Andreina Marques Mejias; Mary Jane Marchisotto; Rosan Meyer; Charlotte G. Mortz; Beatriz Moya; Antonella Muraro; Caroline Nilsson; Lucila Camargo Lopes de Oliveira; Liam O’mahony; Nikolaos G Papadopoulos; Kirsten P. Perrett; Rachel Peters; Marcia Podesta; Lars K Poulsen; Graham  Roberts; Hugh Sampson; Jürgen Schwarze; Peter Smith; Elizabeth Tham; Eva Untersmayr; Ronald van Ree; Carina Venter; Brian  Vickery; Berber Vlieg-Boerstra; Thomas Werfel; Margitta Worm; George  du Toit; Isabel Skypala

doi:10.1111/all.16345

EAACI Guidelines on the Management of IgE-mediated Food Allergy

Alexandra F Santos, Carmen Riggioni, Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, Alberto Alvarez-Perea, Monsterrat Alvaro-Perea, Barbara Ballmer-Weber, Simona Barni, Kirsten Beyer, Carsten Bindslev-Jensen, Helen A. Brough, Betul Buyuktiryaki, Derek Chu, Stefano Del Giacco, Audrey Dunn Galvin, Bernadette Eberlein, Motohiro Ebisawa, Philippe Eigenmann, Thomas EiweggerMary Feeney, Monsterrat Fernandez-Rivas, Alessandro Fiocchi, Helen R. Fisher, David M. Fleischer, Mattia Giovannini, Claudia Gray, Karin Hoffmann-sommergruber, Susanne Halken, Jonathan O'B Hourihane, Christina J. Jones, Marek Jutel, Edward F Knol, George N. Konstantinou, Gideon Lack, Susanne Lau, Andreina Marques Mejias, Mary Jane Marchisotto, Rosan Meyer, Charlotte G. Mortz, Beatriz Moya, Antonella Muraro, Caroline Nilsson, Lucila Camargo Lopes de Oliveira, Liam O’mahony, Nikolaos G Papadopoulos, Kirsten P. Perrett, Rachel Peters, Marcia Podesta, Lars K Poulsen, Graham Roberts, Hugh Sampson, Jürgen Schwarze, Peter Smith, Elizabeth Tham, Eva Untersmayr, Ronald van Ree, Carina Venter, Brian Vickery, Berber Vlieg-Boerstra, Thomas Werfel, Margitta Worm, George du Toit, Isabel Skypala

Research output: Contribution to journal › Review article › peer-review

Abstract

This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.

Original language	English
Journal	Allergy
DOIs	https://doi.org/10.1111/all.16345
Publication status	Published - 30 Oct 2024

Keywords / Materials (for Non-textual outputs)

biologicals
treatment
allergen immunotherapy
management
anaphylaxis
diet
IgE-mediated food allergy
food allergy

Access to Document

10.1111/all.16345

EAACI Guidelines on the Management of IgE-mediated Food Allergy R1 CleanAccepted author manuscript, 1.26 MB
Allergy - 2024 - Santos - EAACI guidelines on the management of IgE‐mediated food allergyFinal published version, 2.7 MB

Cite this

Santos, A. F., Riggioni, C., Agache, I., Akdis, C. A., Akdis, M., Alvarez-Perea, A., Alvaro-Perea, M., Ballmer-Weber, B., Barni, S., Beyer, K., Bindslev-Jensen, C., Brough, H. A., Buyuktiryaki, B., Chu, D., Del Giacco, S., Galvin, A. D., Eberlein, B., Ebisawa, M., Eigenmann, P., ... Skypala, I. (2024). EAACI Guidelines on the Management of IgE-mediated Food Allergy. Allergy. https://doi.org/10.1111/all.16345

@article{cd7424026d05460995154aebc9a49dc7,

title = "EAACI Guidelines on the Management of IgE-mediated Food Allergy",

abstract = "This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes. ",

keywords = "biologicals, treatment, allergen immunotherapy, management, anaphylaxis, diet, IgE-mediated food allergy, food allergy",

author = "Santos, {Alexandra F} and Carmen Riggioni and Ioana Agache and Akdis, {Cezmi A} and Mubeccel Akdis and Alberto Alvarez-Perea and Monsterrat Alvaro-Perea and Barbara Ballmer-Weber and Simona Barni and Kirsten Beyer and Carsten Bindslev-Jensen and Brough, {Helen A.} and Betul Buyuktiryaki and Derek Chu and {Del Giacco}, Stefano and Galvin, {Audrey Dunn} and Bernadette Eberlein and Motohiro Ebisawa and Philippe Eigenmann and Thomas Eiwegger and Mary Feeney and Monsterrat Fernandez-Rivas and Alessandro Fiocchi and Fisher, {Helen R.} and Fleischer, {David M.} and Mattia Giovannini and Claudia Gray and Karin Hoffmann-sommergruber and Susanne Halken and Hourihane, {Jonathan O'B} and Jones, {Christina J.} and Marek Jutel and Knol, {Edward F} and Konstantinou, {George N.} and Gideon Lack and Susanne Lau and {Marques Mejias}, Andreina and Marchisotto, {Mary Jane} and Rosan Meyer and Mortz, {Charlotte G.} and Beatriz Moya and Antonella Muraro and Caroline Nilsson and {Camargo Lopes de Oliveira}, Lucila and Liam O{\textquoteright}mahony and Papadopoulos, {Nikolaos G} and Perrett, {Kirsten P.} and Rachel Peters and Marcia Podesta and Poulsen, {Lars K} and Graham Roberts and Hugh Sampson and J{\"u}rgen Schwarze and Peter Smith and Elizabeth Tham and Eva Untersmayr and {van Ree}, Ronald and Carina Venter and Brian Vickery and Berber Vlieg-Boerstra and Thomas Werfel and Margitta Worm and {du Toit}, George and Isabel Skypala",

year = "2024",

month = oct,

day = "30",

doi = "10.1111/all.16345",

language = "English",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

}

Santos, AF, Riggioni, C, Agache, I, Akdis, CA, Akdis, M, Alvarez-Perea, A, Alvaro-Perea, M, Ballmer-Weber, B, Barni, S, Beyer, K, Bindslev-Jensen, C, Brough, HA, Buyuktiryaki, B, Chu, D, Del Giacco, S, Galvin, AD, Eberlein, B, Ebisawa, M, Eigenmann, P, Eiwegger, T, Feeney, M, Fernandez-Rivas, M, Fiocchi, A, Fisher, HR, Fleischer, DM, Giovannini, M, Gray, C, Hoffmann-sommergruber, K, Halken, S, Hourihane, JOB, Jones, CJ, Jutel, M, Knol, EF, Konstantinou, GN, Lack, G, Lau, S, Marques Mejias, A, Marchisotto, MJ, Meyer, R, Mortz, CG, Moya, B, Muraro, A, Nilsson, C, Camargo Lopes de Oliveira, L, O’mahony, L, Papadopoulos, NG, Perrett, KP, Peters, R, Podesta, M, Poulsen, LK, Roberts, G, Sampson, H, Schwarze, J, Smith, P, Tham, E, Untersmayr, E, van Ree, R, Venter, C, Vickery, B, Vlieg-Boerstra, B, Werfel, T, Worm, M, du Toit, G & Skypala, I 2024, 'EAACI Guidelines on the Management of IgE-mediated Food Allergy', Allergy. https://doi.org/10.1111/all.16345

TY - JOUR

T1 - EAACI Guidelines on the Management of IgE-mediated Food Allergy

AU - Santos, Alexandra F

AU - Riggioni, Carmen

AU - Agache, Ioana

AU - Akdis, Cezmi A

AU - Akdis, Mubeccel

AU - Alvarez-Perea, Alberto

AU - Alvaro-Perea, Monsterrat

AU - Ballmer-Weber, Barbara

AU - Barni, Simona

AU - Beyer, Kirsten

AU - Bindslev-Jensen, Carsten

AU - Brough, Helen A.

AU - Buyuktiryaki, Betul

AU - Chu, Derek

AU - Del Giacco, Stefano

AU - Galvin, Audrey Dunn

AU - Eberlein, Bernadette

AU - Ebisawa, Motohiro

AU - Eigenmann, Philippe

AU - Eiwegger, Thomas

AU - Feeney, Mary

AU - Fernandez-Rivas, Monsterrat

AU - Fiocchi, Alessandro

AU - Fisher, Helen R.

AU - Fleischer, David M.

AU - Giovannini, Mattia

AU - Gray, Claudia

AU - Hoffmann-sommergruber, Karin

AU - Halken, Susanne

AU - Hourihane, Jonathan O'B

AU - Jones, Christina J.

AU - Jutel, Marek

AU - Knol, Edward F

AU - Konstantinou, George N.

AU - Lack, Gideon

AU - Lau, Susanne

AU - Marques Mejias, Andreina

AU - Marchisotto, Mary Jane

AU - Meyer, Rosan

AU - Mortz, Charlotte G.

AU - Moya, Beatriz

AU - Muraro, Antonella

AU - Nilsson, Caroline

AU - Camargo Lopes de Oliveira, Lucila

AU - O’mahony, Liam

AU - Papadopoulos, Nikolaos G

AU - Perrett, Kirsten P.

AU - Peters, Rachel

AU - Podesta, Marcia

AU - Poulsen, Lars K

AU - Roberts, Graham

AU - Sampson, Hugh

AU - Schwarze, Jürgen

AU - Smith, Peter

AU - Tham, Elizabeth

AU - Untersmayr, Eva

AU - van Ree, Ronald

AU - Venter, Carina

AU - Vickery, Brian

AU - Vlieg-Boerstra, Berber

AU - Werfel, Thomas

AU - Worm, Margitta

AU - du Toit, George

AU - Skypala, Isabel

PY - 2024/10/30

Y1 - 2024/10/30

N2 - This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.

AB - This European Academy of Allergy and Clinical Immunology (EAACI) guideline provides recommendations for the management of IgE-mediated food allergy and was developed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Following the confirmation of IgE-mediated food allergy diagnosis, allergen avoidance and dietary advice (with support of a specialised dietitian, if possible) together with the provision of a written treatment plan, education on the recognition of allergic symptoms and prescription of medication including adrenaline using an auto-injector are essential. Patients with significant anxiety and requirement for coping strategies may benefit from support from a clinical psychologist. As immunomodulatory interventions, omalizumab is suggested for treatment of IgE-mediated food allergy in children from the age of 1 and adults; and oral allergen-specific immunotherapy is recommended for children and adolescents with peanut allergy and suggested for milk and egg allergies (generally after 4 years of age for milk and egg). Sublingual and epicutaneous immunotherapy are suggested for peanut allergy but are not yet available at the point of care. Future research into disease modifying treatments for IgE-mediated food allergy are highly needed, with standardised and patient-focused protocols and outcomes.

KW - biologicals

KW - treatment

KW - allergen immunotherapy

KW - management

KW - anaphylaxis

KW - diet

KW - IgE-mediated food allergy

KW - food allergy

U2 - 10.1111/all.16345

DO - 10.1111/all.16345

M3 - Review article

SN - 0105-4538

JO - Allergy

JF - Allergy

ER -

EAACI Guidelines on the Management of IgE-mediated Food Allergy

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this